Crossref

1. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir

- Fa- Da Wang

- Jing Zhou

- Lan-Qing Li

- Yu-Jing Li

- Meng-Lan Wang

- Ya-Chao Tao

- Dong-Mei Zhang

- Yong-Hong Wang

- En-Qiang Chen

2. Tenofovir-alafenamide

3. Real-life data of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in the patients with chronic hepatitis B: a single-center experience

- Mustafa AKAR

4. Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis

- Ping‐Yu Hsu

- Hui‐Chen Su

- Mi‐Chia Ma

- Chien‐An Chen

- Sin‐Yi Yu

- Yi‐Ming Hua

5. The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study

- Fethiye Akgul

- Yusuf Arslan

- Mehmet Celik

- Omer Karasahin

- Mustafa Kemal Celen

6. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis

- Kexin Tong

- Mingjing Chen

- Danni Wang

- Haifeng Dai

- Jiayi Peng

- Jia Zhang

- Jiao Zhou

- Yujiao Chang

- Wenxiang Huang